PositiveID Corporation Expands Firefly Dx Testing Capabilities for Hospital Acquired Infection (HAI) Market

PositiveID Corporation (“PositiveID” or “Company”), a developer of biological detection and diagnostics solutions, announced today that it has successfully detected Clostridium difficile (“C. diff”) on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”) in less than 20 minutes.

The C. diff assay, provided to the Company for testing by partner GenArraytion, Inc., is a more comprehensive and specific test than many other C. diff assays on the market as it tests for the C. diff chromosome as well as both Toxin A and Toxin B.

Clostridium difficile (C. diff.)  is a bacterium that most often affects older patients in hospitals or long-term care facilities after antibiotic use, and causes symptoms ranging from diarrhea to lethal inflammation of the colon.

In addition to C. diff, the Company recently announced its successful detection of

methicillin-resistant Staphylococcus aureus (“MRSA”), another common hospital-acquired infection, on its Firefly Dx prototype system. It has also successfully identified methicillin-susceptible Staphylococcus aureus (“MSSA”).

To read this news article in its entirety click on the following link

https://ca.finance.yahoo.com/news/positiveid-expands-firefly-dx-testing-123000203.html